Liplat

Pravastatin, the active ingredient in Liplat, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol levels and is indicated for patients with hypercholesterolemia and those at risk of cardiovascular events. It is prescribed for the primary and secondary prevention of atherosclerotic cardiovascular disease.

GNH USA supplies Liplat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Pravastatin is used to manage disorders of lipid metabolism and to reduce cardiovascular risk. - Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Primary hyperlipidemia: improves lipid profile and lowers triglycerides. - Cardiovascular risk reduction: decreases incidence of myocardial infarction, stroke and related events in patients with established risk factors.

Pravastatin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild headache reported in some patients. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: transient increase in ALT or AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: significant elevation of liver enzymes or hepatitis. - Allergic reactions: rash, pruritus or angioedema.

Before initiating pravastatin therapy, several precautions should be considered. - Liver function assessment: obtain baseline hepatic enzymes and monitor periodically. - Renal impairment: adjust dose or avoid in severe renal dysfunction. - Drug interactions: review concomitant medications that affect statin metabolism. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Pravastatin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: markedly increases pravastatin plasma concentrations, raising risk of myopathy. - Gemfibrozil: synergistic effect on muscle toxicity, may precipitate rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Amiodarone: may modestly raise statin levels, monitor for muscle symptoms. - Antacids (aluminum or magnesium): can reduce pravastatin absorption, separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect, check INR more frequently.